Navigation Links
VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291
Date:2/25/2009

SAN FRANCISCO, Feb. 25 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced the issuance of United States Patent No. 7,495,024 entitled "Phenylalkyl N-Hydroxyureas for Combating Atherosclerotic Plaque", covering the use of VIA's lead compound, VIA-2291, for the treatment of atherosclerosis. This patent is also pending in other major markets worldwide.

VIA-2291, which is currently in Phase II development for the treatment of cardiovascular disease caused by atherosclerosis, targets inflammation in the blood vessel wall, an underlying cause of atherosclerosis. A growing body of scientific evidence and data from the VIA-2291 clinical program points to reduction of inflammation and inflammatory processes in the vessel wall as a critical step in combating cardiovascular disease and its complications, including heart attack and stroke.

"Our clinical trial results presented at the most recent meeting of the American Heart Association in New Orleans provides important evidence for VIA-2291's effect on reducing vascular inflammation. This patent is an important step in the commercial development of the compound by providing VIA with exclusivity in this very large and underserved market through 2026," said Lawrence K. Cohen, Ph.D., chief executive officer of VIA Pharmaceuticals. "We are pleased with the issuance of this important patent as it further strengthens and builds on our existing intellectual property protection for our lead clinical compound."

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candida
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Product and ... very low abundance and are often “lost in ... time-consuming. , Join presenters Dr. Rowel Tobias, Senior ... John Anders, Head of Quality at Nanotherapeutics, Inc., ... that can speed detection and quantitation while achieving ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, ... announce the relaunch of his highly informative blog, now named ... “ What are Stem Cells ?” Dr. Harman’s purpose ... in the basics of stem cell therapy so that pet ... of treatment when considering regenerative medicine. , A veterinarian by ...
(Date:7/10/2014)... 10, 2014 On July 9 ... , presented Russia,s first national ... The Company is developing a unique project called ... develops a number of innovative drugs based on monoclonal ... ceremony took place at the International Exhibition "Innoprom 2014" ...
(Date:7/10/2014)... D.C., April 15, 2014 -- According to the ... to nuclear security comes from terrorists acquiring sufficient ... to construct a crude nuclear explosive device. The ... nuclear trafficking have involved gram-level quantities, which can ... , According to a new study appearing this ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Sensitive detection method may help impede illicit nuclear trafficking 2
... 7, 2011 Regado Biosciences, Inc., a privately ... with active control agents, announced the presentation of ... Company,s Phase 2b RADAR trial of REG1, Regado,s ... at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium meeting ...
... Inc. (NYSE AMEX: IBIO ) today announced that ... its 2011 Annual Stockholders Meeting to be held December 8, 2011 ... at 11:00 AM ET. Although only stockholders of ... will be entitled to vote at the meeting, anyone with proof ...
... The shortlist of contenders for the highest ... narrowed tonight as the winners of the Siemens ... Finals were announced.  Cancer stem cell research earned ... Angela Zhang of Cupertino, California.  Research on molecular ...
Cached Biology Technology:Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011 2Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011 3Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011 4iBio Sets Record Date and Location for December 8 Annual Meeting of Stockholders 2Biochemistry and Bioengineering Research Brings California Students Closer to Nation's Highest Science Honor for High School Students 2Biochemistry and Bioengineering Research Brings California Students Closer to Nation's Highest Science Honor for High School Students 3Biochemistry and Bioengineering Research Brings California Students Closer to Nation's Highest Science Honor for High School Students 4Biochemistry and Bioengineering Research Brings California Students Closer to Nation's Highest Science Honor for High School Students 5
(Date:7/11/2014)... The increased risk of kidney injury related to ... reflects the mass of HES molecules, according to a ... of the International Anesthesia Research Society (IARS). , The ... of HES on cultured human renal proximal tubule cells ... and colleagues of University Hospital Wrzburg, Austria. Other ...
(Date:7/11/2014)... 1 can inhibit voltage-gated calcium channel, decrease ... However, some scholars demonstrated that cannabinoid receptor ... and increase neurotransmitter release. Dr. Yi Zhang ... Tongji Medical College, Huazhong University of Science ... and calcium imaging in cultured trigeminal ganglion ...
(Date:7/10/2014)... In Santa Fe, Albuquerque, and other major cities in ... watered with treated municipal wastewater rather than precious potable ... more than 40% of all golf courses receive treated ... courses. , Additionally, golf courses and homeowners alike ... nutrient in fertilizer is nitrate. A New Mexico State ...
Breaking Biology News(10 mins):In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2'Tailored' water -- the latest in lawn care 2
... -- Findings from a first-of-its-kind study by Indiana University ... or fantasies -- can lead to female orgasm. ... phenomenon, sometimes called "coregasm" because of its association with ... media for years, said Debby Herbenick, co-director of the ...
... Georgetown University Medical Center have revealed how a mutation in ... to effectively pass along appetite suppressing signals from the body ... obesity caused by a voracious appetite. , Their study, published ... might be a way to stimulate expression of that gene ...
... a proton the bare nucleus of a hydrogen atom ... a molecule, the result is a hydrogen bond, in which ... electrons. Conventional wisdom has it that proton transfers can only ... networks that can connect and reconnect to alter molecular properties. ...
Cached Biology News:Study: Exercise can lead to female orgasm, sexual pleasure 2Study: Exercise can lead to female orgasm, sexual pleasure 3Researchers reveal how a single gene mutation leads to uncontrolled obesity 2A surprising new kind of proton transfer 2A surprising new kind of proton transfer 3A surprising new kind of proton transfer 4
Mouse monoclonal antibody raised against a full length recombinant YARS. NCBI Entrez Gene ID = YARS...
... Sight DS-L2 imaging controller is a successor ... and allows users to comfortably observe, record ... controller features an 8.4 inch LCD (XGA) ... of Nikon cameras including the DS-Fi1 , ...
... is a premium quality recombinant form of ... is suitable for a wide range of ... and reproducible performance, each preparation is extensively ... assays. NovaTaq DNA Polymerase possesses an integral ...
Mouse polyclonal antibody raised against a partial recombinant TSEN2. NCBI Entrez Gene ID = 80746...
Biology Products: